Pirfenidone Tablet, Coated
Product Images NDC 71335-2984

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 71335-2984). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352984)

Label for Pirfenidone Tablets, 801 mg, oral coated tablets. Contains 90 tablets per package. Labeled by Bryant Ranch Prepack and manufactured by Alembic Pharmaceuticals Limited. Includes storage instructions and QR codes for package insert and dosage information. Displays NDC 71335-2984-1 and barcodes.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

Cumulative distribution chart depicting the percentage of patients over absolute change in %FVC from baseline to week 52, comparing Pirfenidone and placebo groups. The x-axis shows change in %FVC, ranging from -30% to +10%, and the y-axis shows the percentage of patients from 0% to 100%. Two curves are plotted: a solid line for Pirfenidone (n=278) and a dotted line for placebo (n=277), showing differences in patient distribution across worsening and no decline regions.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

A line graph comparing mean change in forced vital capacity (FVC) in milliliters over 52 weeks between two groups: Pirfenidone (n=278) and Placebo (n=277). The Pirfenidone group shows a smaller decline in FVC over time compared to the Placebo group, indicated by the solid and dashed lines respectively.*

FDA Label Image

Figure 3 (Pirfenidone Figure3)

Survival curve chart comparing percentage of patients alive over time in weeks for Pirfenidone (801 mg) versus placebo groups. The chart includes patient counts at risk at multiple time points up to 120 weeks, with hazard ratio and confidence interval values shown. The solid line represents Pirfenidone, and the dotted line represents placebo.*

FDA Label Image

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)

A dosing schedule table for Pirfenidone Tablets 267 mg showing the number of tablets to be taken morning, afternoon, and evening over three time periods: Days 1 to 7 (1 tablet each time, total 3), Days 8 to 14 (2 tablets each time, total 6), and from Day 15 onward (3 tablets each time, total 9).*

FDA Label Image

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)

A dosing schedule table for Pirfenidone Tablets 801 mg showing the number of pills to be taken at three times during the day—morning (breakfast), afternoon (lunch), and evening (dinner)—from day 15 onward. The total number of pills each day is three.*

FDA Label Image

Pirfenidone (Pirfenidone Structure)

Chemical structure of the active ingredient pirfenidone, showing its molecular framework with aromatic rings and functional groups, as typically represented in pharmaceutical labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.